STERIS Posts Strong FY25 Growth, Net Income Jumps 18.6%

TL;DR

**STERIS is a buy; healthcare demand is driving strong revenue and profit growth, making it a solid defensive play.**

AI Summary

STERIS plc reported robust financial performance for the fiscal year ended March 31, 2025, with total revenue reaching $5.36 billion, marking a 7.8% increase from the prior year's $4.97 billion. Net income attributable to STERIS plc shareholders was $605.2 million, a significant rise from $510.1 million in the previous fiscal year. The company's gross profit stood at $2.38 billion, up from $2.21 billion in fiscal year 2024, reflecting effective cost management and strong sales in both product and service segments. Product revenue increased to $3.51 billion from $3.25 billion, while service revenue grew to $1.85 billion from $1.72 billion. STERIS continued to focus on its core healthcare and life sciences segments, leveraging its sterilization and infection prevention solutions. Key risks include global supply chain disruptions and intense competition in the medical device and pharmaceutical services markets. The strategic outlook emphasizes continued innovation and market expansion, particularly in emerging markets, to sustain its growth trajectory.

Why It Matters

STERIS's strong performance, with an 18.6% jump in net income, signals robust demand for its critical sterilization and infection prevention solutions, which are essential across healthcare and life sciences. This growth positions STERIS favorably against competitors like Cantel Medical and Getinge, demonstrating its ability to capture market share and maintain pricing power. For investors, this indicates a resilient business model with consistent profitability and potential for continued dividend growth. Employees benefit from a stable and expanding company, while customers can rely on STERIS for vital products and services that ensure patient safety and product integrity in a highly regulated environment.

Risk Assessment

Risk Level: medium — The risk level is medium due to STERIS's reliance on global supply chains and intense competition. While revenue grew to $5.36 billion, the company operates in a highly regulated industry susceptible to unforeseen disruptions, as evidenced by potential supply chain volatility impacting product availability and costs. Furthermore, the competitive landscape, with numerous established players, could pressure margins despite the current strong performance.

Analyst Insight

Investors should consider STERIS plc (STE) for its consistent growth in essential healthcare sectors and strong financial performance, including an 18.6% increase in net income. The company's robust revenue of $5.36 billion and strategic focus on innovation suggest continued stability and potential for long-term capital appreciation.

Financial Highlights

revenue

$5.36B

net Income

$605.2M

gross Margin

44.4%

revenue Growth

+7.8%

Revenue Breakdown

Key Numbers

• $5.36B — Total Revenue (Increased 7.8% from $4.97 billion in FY2024 to $5.36 billion in FY2025.)
• $605.2M — Net Income (Increased 18.6% from $510.1 million in FY2024 to $605.2 million in FY2025.)
• $2.38B — Gross Profit (Increased from $2.21 billion in FY2024 to $2.38 billion in FY2025.)
• $3.51B — Product Revenue (Increased from $3.25 billion in FY2024 to $3.51 billion in FY2025.)
• $1.85B — Service Revenue (Increased from $1.72 billion in FY2024 to $1.85 billion in FY2025.)
• 7.8% — Revenue Growth (Year-over-year increase in total revenue from FY2024 to FY2025.)
• 18.6% — Net Income Growth (Year-over-year increase in net income from FY2024 to FY2025.)

Key Players & Entities

• STERIS plc (company) — filer of 10-K
• $5.36 billion (dollar_amount) — total revenue for fiscal year 2025
• $605.2 million (dollar_amount) — net income attributable to STERIS plc shareholders for fiscal year 2025
• $4.97 billion (dollar_amount) — total revenue for fiscal year 2024
• $510.1 million (dollar_amount) — net income attributable to STERIS plc shareholders for fiscal year 2024
• $2.38 billion (dollar_amount) — gross profit for fiscal year 2025
• $2.21 billion (dollar_amount) — gross profit for fiscal year 2024
• $3.51 billion (dollar_amount) — product revenue for fiscal year 2025
• $1.85 billion (dollar_amount) — service revenue for fiscal year 2025
• Cantel Medical (company) — competitor

FAQ

Risk Factors

• Supply Chain Disruptions [medium — operational]: Global supply chain disruptions pose a significant risk, potentially impacting the availability and cost of raw materials and components necessary for product manufacturing. The company's ability to manage these disruptions is critical for maintaining production levels and meeting customer demand.
• Intense Competition [medium — market]: STERIS operates in highly competitive markets, including medical devices and pharmaceutical services. Intense competition from both established players and new entrants could pressure pricing and market share, requiring continuous innovation and strategic differentiation.
• Regulatory Compliance [medium — regulatory]: The company's products and services are subject to stringent regulatory requirements in various jurisdictions. Changes in regulations or failure to comply could result in product recalls, fines, or reputational damage, impacting financial performance.

Industry Context

STERIS plc operates within the healthcare and life sciences industries, focusing on sterilization, infection prevention, and surgical products. The sector is characterized by continuous innovation, stringent regulatory oversight, and a growing demand for advanced medical technologies and services, driven by an aging global population and increased healthcare spending.

Regulatory Implications

STERIS's operations are subject to extensive regulatory frameworks globally, including those governing medical devices and pharmaceutical manufacturing. Compliance with FDA, EMA, and other health authority regulations is paramount. Any changes in these regulations or non-compliance could significantly impact product approvals, market access, and operational costs.

What Investors Should Do

1. Monitor supply chain resilience strategies.
2. Evaluate competitive positioning and innovation pipeline.
3. Assess impact of regulatory changes.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC) that gives a comprehensive summary of a company's financial performance. (This document provides the detailed financial and operational information for STERIS plc for the fiscal year ended March 31, 2025.)

Fiscal Year End

The last day of a company's accounting period, which does not necessarily coincide with the calendar year end. (STERIS plc's fiscal year ends on March 31st, as indicated in the filing.)

Gross Profit

The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. (STERIS reported a gross profit of $2.38 billion, indicating effective cost management relative to its revenue.)

Net Income

The profit remaining after all expenses, including taxes and interest, have been deducted from total revenue. (STERIS's net income of $605.2 million shows a strong increase, reflecting improved profitability.)

Year-Over-Year Comparison

STERIS plc demonstrated strong year-over-year performance, with total revenue increasing by 7.8% to $5.36 billion and net income surging by 18.6% to $605.2 million. Gross profit also saw a healthy increase, indicating improved operational efficiency or favorable pricing. No new significant risks were highlighted in the summary, suggesting a stable risk profile compared to the prior period, though existing risks like supply chain and competition remain relevant.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on May 29, 2025 regarding STERIS plc (STE).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR